Christine Pattison

Quantitative Measurement of Changes in Amyloid-β(40) in the Rat Brain and Cerebrospinal Fluid following Treatment with the γ-Secretase Inhibitor LY-411575 [N2-[(2 S)-2-(3,5-Difluorophenyl)-2-hydroxyethanoyl]-N1-[(7 S)-5-methyl-6-oxo-6,7-dihydro-5 H-dibenzo[b,d]azepin-7-yl]-l-alaninamide]

Jonathan D. Best, Mark T. Jay, Franklin Otu et al. · Journal of Pharmacology and Experimental Therapeutics · 2005 · 98 citations

Medicine, Neuroscience, Pharmacology +14

In Vivo Characterization of Aβ(40) Changes in Brain and Cerebrospinal Fluid Using the Novel γ-Secretase Inhibitor N-[cis-4-[(4-Chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide (MRK-560) in the Rat

Jonathan D. Best, Mark T. Jay, Franklin Otu et al. · Journal of Pharmacology and Experimental Therapeutics · 2006 · 64 citations

Life Sciences, Neuroscience, Pharmacology +17

Metabolism, Excretion, and Pharmacokinetics of Selumetinib, an MEK1/2 inhibitor, in Healthy Adult Male Subjects

Angela W. Dymond, Colin Howes, Christine Pattison et al. · Clinical Therapeutics · 2016 · 33 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +10

3,4-Fused cyclohexyl sulfones as γ-secretase inhibitors

Duncan Shaw, Jonathan D. Best, Kevin Dinnell et al. · Bioorganic & Medicinal Chemistry Letters · 2006 · 31 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +6

Utility of Long-Term Cultured Human Hepatocytes as an in Vitro Model for Cytochrome P450 Induction

Georgina Meneses‐Lorente, Christine Pattison, Claire Guyomard et al. · Drug Metabolism and Disposition · 2006 · 21 citations

Medicine, Pharmacology, Toxicology +16